Astellas Pharma, Inc.

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company formed in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. It discovers, develops, manufactures, and commercializes innovative therapies across key therapeutic areas including oncology, urology, ophthalmology, immunology, and women's health. Notable products encompass XTANDI for prostate cancer, PADCEV for urothelial cancer, VEOZAH for vasomotor symptoms, Myrbetriq for overactive bladder, and Prograf for immunosuppression in transplantation. With headquarters in Tokyo and operations in over 70 countries, Astellas employs more than 13,600 people and maintains R&D facilities in Japan, the United States, Europe, and Asia. The company emphasizes specialty pharmaceuticals, advancing pipelines in immuno-oncology, gene therapy, mitochondrial disorders, rare blindness, regenerative medicine, and targeted protein degradation. Strategic partnerships with firms like Pfizer and Merck enhance its development efforts, while a robust acquisition history bolsters its position as a challenger in the global pharmaceuticals industry, generating annual revenues around $12.5-13.2 billion.